Skip to main content

NASDAQ:XFOR - X4 Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.00
  • Forecasted Upside: 122.22 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$8.10
▲ +0.05 (0.62%)
1 month | 3 months | 12 months
Get New X4 Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XFOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XFOR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$18.00
▲ +122.22% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for X4 Pharmaceuticals in the last 3 months. The average price target is $18.00, with a high forecast of $21.00 and a low forecast of $15.00. The average price target represents a 122.22% upside from the last price of $8.10.

Buy

The current consensus among 4 contributing investment analysts is to buy stock in X4 Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/16/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/14/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/12/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/10/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/9/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2021OppenheimerReiterated RatingBuy$16.00High
i
12/17/2020Brookline Capital ManagementInitiated CoverageBuy$21.00High
i
Rating by L. Cann at Brookline Capital Management
11/30/2020B. RileyReiterated RatingBuy$15.00Medium
i
Rating by Mayank Mamtani at B. Riley
11/9/2020Canaccord GenuityLower Price TargetBuy$22.00 ➝ $20.00High
i
6/12/2020B. RileyReiterated RatingBuy$15.00Medium
i
Rating by Mayank Mamtani at B. Riley
5/26/2020Canaccord GenuityReiterated RatingBuyHigh
i
5/8/2020B. RileyLower Price TargetBuy$19.00 ➝ $15.00Medium
i
Rating by Mayank Mamtani at B. Riley
5/8/2020HC WainwrightLower Price TargetOutperform$22.00 ➝ $21.00Medium
i
Rating by S. Ramakanth at HC Wainwright
5/7/2020OppenheimerReiterated RatingBuy$20.00Medium
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
4/12/2020HC WainwrightReiterated RatingBuy$22.00High
i
Rating by S. Ramakanth at HC Wainwright
3/26/2020CitigroupLower Price TargetBuy$16.00 ➝ $15.00High
i
Rating by Joel Beatty at Citigroup Inc.
3/13/2020B. RileyLower Price TargetBuy$25.00 ➝ $19.00Medium
i
Rating by Mayank Mamtani at B. Riley
3/12/2020CowenReiterated RatingBuyMedium
i
Rating by Marc Frahm at Cowen Inc
2/13/2020Roth CapitalReiterated RatingBuyMedium
i
Rating by Zegbeh Jallah at Roth Capital
1/7/2020HC WainwrightInitiated CoverageBuy$22.00Low
i
Rating by S. Ramakanth at HC Wainwright
12/23/2019OppenheimerInitiated CoverageOutperform$20.00High
i
12/18/2019Roth CapitalInitiated CoverageBuy$20.00Medium
i
12/9/2019CitigroupUpgradeNeutral ➝ Buy$16.00 ➝ $20.00Medium
i
12/5/2019B. RileyInitiated CoverageBuy$25.00High
i
10/10/2019CowenReiterated RatingBuyLow
i
Rating by Marc Frahm at Cowen Inc
9/30/2019CowenReiterated RatingBuyLow
i
Rating by Marc Frahm at Cowen Inc
6/7/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$27.00High
i
6/5/2019CowenInitiated CoverageOutperform ➝ OutperformLow
i
5/21/2019Canaccord GenuityInitiated CoverageBuy$27.00Medium
i
(Data available from 5/10/2016 forward)
X4 Pharmaceuticals logo
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rear diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $8.10
$7.92
$8.14

50 Day Range

MA: $8.93
$8.00
$10.28

52 Week Range

Now: $8.10
$5.38
$11.11

Volume

1,819 shs

Average Volume

106,507 shs

Market Capitalization

$140.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.53

Frequently Asked Questions

What sell-side analysts currently cover shares of X4 Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on X4 Pharmaceuticals in the last twelve months: B. Riley, Brookline Capital Management, Canaccord Genuity, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for XFOR.

What is the current price target for X4 Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for X4 Pharmaceuticals in the last year. Their average twelve-month price target is $18.00, suggesting a possible upside of 122.2%. Brookline Capital Management has the highest price target set, predicting XFOR will reach $21.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $15.00 for X4 Pharmaceuticals in the next year.
View the latest price targets for XFOR.

What is the current consensus analyst rating for X4 Pharmaceuticals?

X4 Pharmaceuticals currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XFOR will outperform the market and that investors should add to their positions of X4 Pharmaceuticals.
View the latest ratings for XFOR.

What other companies compete with X4 Pharmaceuticals?

How do I contact X4 Pharmaceuticals' investor relations team?

X4 Pharmaceuticals' physical mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The company's listed phone number is 857-529-8300 and its investor relations email address is [email protected] The official website for X4 Pharmaceuticals is www.x4pharma.com.